Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

27. **(Previously Presented)** A method for treating extra-reproductive tract tissues that are responsive to treatment with estrogen comprising administering to a patient an effective amount of a nonuterotrophic compound having the structure



(I)

wherein R_1 is $-O(CH_2)_mR_3$ or $-(CH_2)_nR_3$; R_3 is an anionic substituent; m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; and R_2 is para-OH.

28. **(Original)** The method of claim 27 wherein R_1 is $-O(CH_2)_mR_3$.

29. **(Original)** The method of claim 27 wherein R_1 is $-(CH_2)_nR_3$.

30. **(Original)** The method of claim 27 wherein the compound is 4-[1-(4-hydroxyphenyl)-2-phenylethyl]phenoxyacetic acid such that R_1 is para-OCH_2R_3; and R_3 is $-COO^-$.

31. **(Original)** The method of claim 27 wherein the anionic substituent comprises a functional group selected from the group consisting of a carboxylate group, a tetrazolate group and a bisphosphonate group.

32. **(Original)** The method of claim 27 wherein the patient is a female.

33. **(Original)** The method of claim 32 wherein the patient is a perimenopausal or postmenopausal female.

34. **(Original)** The method of claim 27 wherein the compound is administered in an estrogen replacement therapy.

35. **(Original)** The method of claim 27 wherein the compound is administered to treat osteopenia.

36. **(Original)** A pharmaceutical composition comprising a compound having the structure



(I)

wherein R_1 is $-O(CH_2)_mR_3$ or $-(CH_2)_nR_3$; R_3 is an anionic substituent; m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; and R_2 is para-OH; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

37. **(Original)** The pharmaceutical composition of claim 36 wherein R_1 is $-O(CH_2)_mR_3$.

38. **(Currently Amended)** A ~~The~~ pharmaceutical composition ~~of claim 36~~ comprising a compound having the structure



(I)

wherein R_1 is $-(CH_2)_nR_3$; R_3 is an anionic substituent; m is 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; and R_2 is para-OH; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

39. **(Original)** The pharmaceutical composition of claim 36 wherein the compound is 4-[1-(4-hydroxyphenyl)-2-phenylethyl]phenoxyacetic acid such that R_1 is para-OCH_2R_3; and R_3 is $-COO^-$.